reflecting the lack of direct control by Acrux over Axiron sales, which is distributed by its giant pharmaceutical partner Eli Lilly . We maintain our very high fair value uncertainty rating given the potential impact of an adverse ruling by the FDA on
Feb 23 (Reuters) - Eli Lilly and Co said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug.
Feb 23 (Reuters) - Eli Lilly and Co said it would delay its application to market its once-daily diabetes treatment, basal insulin peglispro, beyond the current quarter.
continued to make progress on its pipeline. Baricitinib, the oral treatment for rheumatoid arthritis that is partnered with Eli Lilly , recently reported positive initial top-line results and will be reporting additional data from its Phase III program
Feb 4 (Reuters) - A Cuban immigrant who pleaded guilty to having a role in the theft of more than $50 million of pharmaceuticals from an Eli Lilly and Co warehouse in northern Connecticut was sentenced on Wednesday to 6-1/4 years in prison.
Feb 2 (Reuters) - The U.S. Food and Drug Administration approved a drug developed by Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc to improve blood sugar control in type-2 diabetes patients, the companies said.
Feb 2 (Reuters) - The U.S. Food and Drug Administration approved a drug developed by Eli Lilly and Co and privately held Boehringer Ingelheim Pharmaceuticals Inc to improve blood sugar control in type-2 diabetes patients, the companies said.
Net sales for Axiron, Acrux's lead product out-licenced to Eli Lilly , for the quarter ended 31 December 2014 totalled USD 47.6 million, up 31% sequentially from USD 36.3 million, but down
Jan 30 (Reuters) - Eli Lilly and Co cut its 2015 revenue forecast, issued earlier this month, as the U.S. drugmaker expects a bigger hit from a stronger dollar.
Jan 30 (Reuters) - U.S. drugmaker Eli Lilly and Co reported a 41 percent fall in quarterly profit, hurt by a stronger dollar and a one-time charge related to a restructuring program.